文献速递神经肿瘤

RO4929097治疗复发/进展性胶质母细胞瘤的II期及药效学研究

A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma.
PubMed 文献 · Neurosurgery · 2021-01-01

该II期及药效学研究评估口服γ分泌酶抑制剂RO4929097在复发/进展性胶质母细胞瘤患者中的疗效与药效学效应。共47例患者接受治疗,其中7例可切除肿瘤者术前术后用药。结果显示6个月无进展生存率仅4%,7例组织样本中仅1例出现神经球形成抑制,提示药物无活性且对神经球形成抑制微弱。

要点

  • RO4929097在复发胶质母细胞瘤中6个月无进展生存率仅4%
  • 7例可评估组织样本中仅1例显示神经球形成抑制
  • 该γ分泌酶抑制剂在复发胶质母细胞瘤中无效

核心结论

  • RO4929097在复发胶质母细胞瘤患者中无活性,且对新鲜组织样本的神经球形成抑制极小。

研究设计与样本

  • II期及药效学研究,纳入复发胶质母细胞瘤患者,分两组:A组不可切除者按标准II期设计用药,B组可切除者术前术后用药,共47例接受治疗。

主要发现

  • 6个月无进展生存率为4%,47例中7例接受肿瘤切除。
  • 7例切除样本中仅1例出现神经球形成抑制。

关键数值与推荐

  • 主要终点为6个月无进展生存率和切除肿瘤样本中神经球形成抑制(目标为抑制50%)。

临床怎么用

  • 不推荐RO4929097用于复发胶质母细胞瘤的临床治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer stem-like cells are a major cause of resistance to therapy in patients with glioblastoma (GBM) as well as other cancers. Tumor cells are maintained in a stem-like proliferative state in large part through the Notch signaling pathway. The function of this pathway in turn depends on gamma secretase activity. Inhibition of this enzyme therefore inhibits the Notch pathway and tumor growth as measured by a reduction in the formation of brain tumor neurospheres in murine models. RO4929097 is an oral gamma secretase inhibitor. OBJECTIVE: To estimate the 6-mo progression-free survival rate (PFS6) in patients with progressive GBM and to inhibit by 50% the generation of neurospheres in fresh tissue resected from patients treated with RO4929097. METHODS: In this phase II and pharmacodynamic study, patients with recurrent GBM received RO4929097 in a study of 2 groups. Group A patients had unresectable disease and received drug in a standard phase II design. Group B patients had resectable disease and received drug before and after surgical resection. Endpoints included PFS6 and the inhibition of neurosphere formation in the resected tumor samples. RESULTS: A total of 47 patients received treatment, 7 of whom had tumor resection. The PFS6 was 4%, and the inhibition of neurosphere formation occurred in 1 of 7 patient samples. CONCLUSION: RO4929097 was inactive in recurrent GBM patients and demonstrated minimal inhibition of neurosphere formation in fresh tissue samples.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Peereboom DM, Ye X, Mikkelsen T, et al. A Phase II and Pharmacodynamic Trial of RO4929097 for Patients With Recurrent/Progressive Glioblastoma. Neurosurgery. 2021. PMID: 33027815. doi:10.1093/neuros/nyaa412

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。